Since deleting UBR5 sensitizes cells to treatment by Cdk4/6 inhibitors, it is possible that current Cdk4/6 inhibitor–based treatments for breast cancer can be improved by developing novel therapeutics targeting Rb degradation through UBR5, which is frequently amplified in these cancers (Fig. 6I). This evidence concerns the gene CDK4 and breast carcinoma.